Nektar Therapeutics (NKTR)
56.77
+0.54
(+0.96%)
USD |
NASDAQ |
Jun 10, 16:00
57.00
+0.23
(+0.41%)
After-Hours: 20:00
Nektar Therapeutics SG&A Expense (Quarterly) : 13.44M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 13.44M |
| December 31, 2025 | 11.18M |
| September 30, 2025 | 16.07M |
| June 30, 2025 | 17.07M |
| March 31, 2025 | 24.35M |
| December 31, 2024 | 17.14M |
| September 30, 2024 | 18.96M |
| June 30, 2024 | 20.51M |
| March 31, 2024 | 20.15M |
| December 31, 2023 | 17.32M |
| September 30, 2023 | 21.15M |
| June 30, 2023 | 17.87M |
| March 31, 2023 | 21.08M |
| December 31, 2022 | 21.94M |
| September 30, 2022 | 22.53M |
| June 30, 2022 | 20.52M |
| March 31, 2022 | 27.34M |
| December 31, 2021 | 32.14M |
| September 30, 2021 | 29.47M |
| June 30, 2021 | 29.56M |
| March 31, 2021 | 31.68M |
| December 31, 2020 | 27.14M |
| September 30, 2020 | 26.98M |
| June 30, 2020 | 24.35M |
| March 31, 2020 | 26.22M |
| Date | Value |
|---|---|
| December 31, 2019 | 27.14M |
| September 30, 2019 | 23.98M |
| June 30, 2019 | 22.58M |
| March 31, 2019 | 25.01M |
| December 31, 2018 | 23.78M |
| September 30, 2018 | 18.72M |
| June 30, 2018 | 20.26M |
| March 31, 2018 | 18.69M |
| December 31, 2017 | 12.34M |
| September 30, 2017 | 12.06M |
| June 30, 2017 | 16.00M |
| March 31, 2017 | 11.98M |
| December 31, 2016 | 12.76M |
| September 30, 2016 | 10.25M |
| June 30, 2016 | 11.04M |
| March 31, 2016 | 10.23M |
| December 31, 2015 | 13.24M |
| September 30, 2015 | 9.544M |
| June 30, 2015 | 10.18M |
| March 31, 2015 | 10.30M |
| December 31, 2014 | 12.25M |
| September 30, 2014 | 9.13M |
| June 30, 2014 | 9.619M |
| March 31, 2014 | 9.928M |
| December 31, 2013 | 9.832M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 2.934B |
| Aquestive Therapeutics, Inc. | 10.98M |
| Esperion Therapeutics, Inc. | 43.12M |
| Alumis, Inc. | 18.61M |
| Tvardi Therapeutics, Inc. | 2.14M |